The vaginal and gastrointestinal microbiomes in gynecologic cancers: A review of applications in etiology, symptoms and treatment
Dana M. Chase(Creighton University), Melissa M. Herbst‐Kralovetz(University of Arizona), Bradley J. Monk(Florida Cancer Specialists & Research Institute), Alison Goulder(University of Arizona), Frédéric Zenhausern(University of Arizona)
Cited by 144
Related Papers
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
Concurrent Chemotherapy and Pelvic Radiation Therapy Compared With Pelvic Radiation Therapy Alone as Adjuvant Therapy After Radical Surgery in High-Risk Early-Stage Cancer of the Cervix
|Journal of Clinical Oncology|2000|2.3k
Estrogen–gut microbiome axis: Physiological and clinical implications
|Maturitas|2017|948
Niraparib monotherapy for late-line treatment of ovarian cancer (QUADRA): a multicentre, open-label, single-arm, phase 2 trial
|The Lancet Oncology|2019|533
The microbiome and gynaecological cancer development, prevention and therapy
|Nature Reviews Urology|2020|463